Alliance Pharma (APH) is continuing with its buy-and-build strategy, having evolved through 35 acquisitions over a period of 20 years into a profitable, cashgenerative, specialty pharma business. The company has a mix of international growth brands – Kelo-cote, MacuShield, Vamousse – and a bedrock of solid, local, low-growth products. A fourth international growth brand in the portfolio, Nizoral, was acquired from J&J on 21 June 2018 in the APAC region. The cash consideration
01 Aug 2018
2018: a year of international progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2018: a year of international progress
Alliance Pharma plc (APH:LON) | 35.0 0 0.0% | Mkt Cap: 189.4m
- Published:
01 Aug 2018 -
Author:
Martin Hall -
Pages:
23
Alliance Pharma (APH) is continuing with its buy-and-build strategy, having evolved through 35 acquisitions over a period of 20 years into a profitable, cashgenerative, specialty pharma business. The company has a mix of international growth brands – Kelo-cote, MacuShield, Vamousse – and a bedrock of solid, local, low-growth products. A fourth international growth brand in the portfolio, Nizoral, was acquired from J&J on 21 June 2018 in the APAC region. The cash consideration